Deal Details
Follow-On Offering
Summary
Baird served as joint-bookrunner on this offering
About
Exact Sciences Corporation (“Exact” or the “Company”) (NASDAQ: EXAS) recently completed a follow-on offering of 11,500,000 shares of common stock at a price of $12.75 per share, generating gross proceeds of $146.6 million. The Company intends to use the net proceeds from the offering to fund efforts to obtain FDA approval of its Cologuard test, to fund Cologuard commercialization activities, to fund product development efforts and for general corporate and working capital purposes.Exact is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. The Company is headquartered in Madison, Wisconsin.
For additional information about this transaction, please contact:
- Date
- April 2014
- Company
- Exact Sciences Corporation
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
